The ImmunoStar 5-HT2C receptor antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat choroid plexus and hippocampus using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500 - 1/1000 in PBS - Bn/Av-HRP technique. Intensification methods such as nickel will approximately double the dilution factor as recommended. The antibody was characterized by immunohistochemistry and Western blot. Western blotting revealed a single band of approximately 70 kD.Preincubation of the antibody with an excess of the synthetic peptide blocked staining. Immunohistochemical staining of rat brain correlates well with Northern analysis, in situ hybridization and receptor autoradiography. BlastP database sequence homology searches confirmed that this sequence is unique to rat, mouse and human 5-HT2C receptors.Photo Description: Gray scale IHC image of coronal rat brain section staining for the 5-HT2C receptor (above) and high magnification image of receptor expression in the cortex of the rat brain (below). The tissue was fixed with 4% formaldehyde/0.05% glutaraldehyde in 0.1 M phosphate buffer, before being removed and prepared for vibratome sectioning. Floating sections were incubated at RT in 10% goat serum in PBS, before standard IHC procedure. Primary antibody was incubated at 1:1000 for 48 hours, goat anti-rabbit secondary was subsequently added for 1 hour after washing with PBS. Light microscopy staining was achieved with standard biotin-streptavidin/HRP procedure and DAB chromogen.

Host:Rabbit

Quantity / Volume:100 µL

State:Liquid

Reacts With: Mouse, Rat

Alternate Names: 5-hydroxytryptamine receptor 2C; 5-HT2C; 5HT-1C; 5-HTR2C; 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled, anti-5-HT 2C

RRID: AB_572212Immunogen: Rat 5-HT2C receptor (439-460)Gene SymbolHtr2cDatabase Links:Entrez Gene: 15560 MouseEntrez Gene: 25187 Rat

阿尔茨海默氏症协会称，阿尔茨海默氏症的研究抗体在帮助科学家找到解决这种疾病和其他痴呆症的方法方面发挥着重要作用，这些疾病和痴呆症影响了全世界4700万人和530万美国人，到2050年，这一数字有望增加两倍。随着婴儿潮一代的年龄增长，预计将有2800万人患上这种疾病，其费用将升至美国医疗保险总支出的近四分之一。

自从Aloysius Alzheimer博士于1906年首次描述这种疾病以来，科学家们在了解这种疾病如何影响大脑方面取得了显着进步。十多年后，理解和治疗的突破为阿尔茨海默氏病患者带来了希望。

这些ImmunoStar抗体已在阿尔茨海默氏症的研究中得到证明。用关键字“阿尔茨海默氏病” 搜索我们出版物的数据库，以查找数百种引用这些抗体的出版物。有关神经科学家的意见，请参阅我们的客户推荐书，以赞扬他们从ImmunoStar获得的结果和服务。我们的抗体稳定，高滴度，并且批次间一致，可确保成功染色并获得极佳的价值。